Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma

Sorafenib, systemic treatment for advanced hepatocellular carcinoma (HCC), and regorafenib, novel second line treatment after sorafenib failure, have efficacy limited by evasive mechanisms of acquired-drug resistance. BCL-2 proteins participate in the response to tyrosine kinase inhibitors; however,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Tutusaus, Anna, Stefanovic, Milica, Boix, Loreto, Cucarull, Blanca, Zamora, Aynara, Blasco, Laura, de Frutos, Pablo García, Reig, Maria, Fernandez-Checa, Jose C., Marí, Montserrat, Colell, Anna, Bruix, Jordi, Morales, Albert
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5908280/
https://ncbi.nlm.nih.gov/pubmed/29682179
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24673
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados